24-month follow-up of Maven4: a Phase IV non-interventional, prospective, Spanish multicenter study to assess the long-term effectiveness of cladribine tablets in real-world clinical practice

被引：0
|
作者：
Aladro-Benito, Yolanda
Saiz, Albert [1 ,2 ]
Costa-Frossard, Lucienne [3 ]
Sanchez Magro, Maria Isabel [4 ]
Rodriguez-Antiguedad, Alfredo [5 ]
机构：
[1] Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Multiplesclerosis Unit, Hosp Clin Barcelona, Barcelona, Spain
[2] Univ Barcelona, Barcelona, Spain
[3] Hosp Ramon & Cajal, Serv Neurol, Unidad Neuroinmunol & Esclerosis Multiple, Madrid, Spain
[4] Merck SLU, Madrid, Spain
[5] Hosp Univ Cruces, BioCruces, Bilbao, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1582/2001
引用
收藏
页码：1008 / 1009
页数：2
相关论文
共 25 条
  • [1] 36 month follow-up of Maven4: a Phase IV non-interventional, prospective, Spanish multicenter study to assess the long term effectiveness of Cladribine tablets in real-world clinical practice
    Aladro-Benito, Yolanda
    Saiz, Albert
    Costa-Frossard, Lucienne
    Rodriguez-Antiguedad, Alfredo
    Sanchez Magro, Maria Isabel
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 660 - 661
  • [2] Maven4: Phase IV non interventional, prospective, Spanish multicenter study to evaluate Cladribine tablets long term effectiveness on real-world clinical practice
    Saiz, A.
    Aladro, Y.
    Costa-Frossard, L.
    Sanchez Magro, I.
    Rodriguez-Antiguedad, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 675 - 676
  • [3] Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
    Aamdal, Elin
    Jacobsen, Kari D.
    Straume, Oddbjorn
    Kersten, Christian
    Herlofsen, Oluf
    Karlsen, Jarle
    Hussain, Israr
    Amundsen, Anita
    Dalhaug, Astrid
    Nyakas, Marta
    Schuster, Cornelia
    Hagene, Kirsten T.
    Holmsen, Kjersti
    Russnes, Hege G.
    Skovlund, Eva
    Kaasa, Stein
    Aamdal, Steinar
    Kyte, Jon A.
    Guren, Tormod K.
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (01) : 100 - 111
  • [4] Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study
    Annunziata Lapolla
    Cesare Berra
    Massimo Boemi
    Antonio Carlo Bossi
    Riccardo Candido
    Graziano Di Cianni
    Simona Frontoni
    Stefano Genovese
    Paola Ponzani
    Vincenzo Provenzano
    Giuseppina T. Russo
    Luigi Sciangula
    Natalino Simioni
    Cristiano Bette
    Antonio Nicolucci
    Advances in Therapy, 2018, 35 : 243 - 253
  • [5] Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study
    Lapolla, Annunziata
    Berra, Cesare
    Boemi, Massimo
    Bossi, Antonio Carlo
    Candido, Riccardo
    Di Cianni, Graziano
    Frontoni, Simona
    Genovese, Stefano
    Ponzani, Paola
    Provenzano, Vincenzo
    Russo, Giuseppina T.
    Sciangula, Luigi
    Simioni, Natalino
    Bette, Cristiano
    Nicolucci, Antonio
    ADVANCES IN THERAPY, 2018, 35 (02) : 243 - 253
  • [6] Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study)
    Blockeel, Christophe
    Griesinger, Georg
    Rago, Rocco
    Larsson, Per
    Sonderegger, Yum Lina Yip
    Riviere, Stephane
    Laven, Joop S. E.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [7] A prospective multicentre, non-interventional, real-world study to assess the pattern of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study)
    Blockeel, C.
    Griesinger, G.
    Rago, R.
    Riviere, S.
    Larsson, P.
    Sonderegger, Y. L. Yip
    Laven, J. S. E.
    HUMAN REPRODUCTION, 2022, 37
  • [8] Interim analysis of real-world effectiveness and usage of recombinant factor IX Fc for surgical haemostasis from the 24-month prospective, non-interventional B-MORE Study
    Glosli, H.
    Peyvandi, F.
    Allsup, D.
    Katsarou, O.
    Berrueco, R.
    Bednar, E.
    Lauer, S.
    Gresko, E.
    Santagostino, E.
    HAEMOPHILIA, 2024, 30 : 55 - 56
  • [9] Real-world effectiveness and usage of recombinant factor IX Fc: Secondary paediatric analysis from the 24-month french, prospective, non-interventional B-SURE study
    Chambost, H.
    Oudot, C.
    Genre-Volot, F.
    Wibaut, B.
    Biron-Andreani, C.
    d'Oiron, R.
    Bayart, S.
    Chamouni, P.
    Harroche, A.
    Vanderbecken, S.
    Zidi, M.
    Lauer, S.
    Palmborg, H.
    Gresko, E.
    HAEMOPHILIA, 2024, 30 : 68 - 69
  • [10] Real-world effectiveness and usage of recombinant factor IX Fc: Interim analysis in paediatric patients from the 24-month, prospective, non-interventional B-MORE study
    Glosli, H.
    Pergantou, H.
    Nolan, B.
    Berrueco, R.
    Ranta, S.
    Al Saleh, M.
    Lauer, S.
    Bednar, E.
    Gresko, E.
    Santagostino, E.
    HAEMOPHILIA, 2024, 30 : 98 - 99
123